Prosecution Insights
Last updated: November 04, 2026
Application No. 18/784,967

Oncidium plant extract and the use for the manufacture of a drug for treating diabetes mellitus, liver protection, preventing acute respiratory distress syndrome (ARDS) thereof

Non-Final OA §101§102§103
Filed
Jul 26, 2024
Priority
Jul 28, 2023 — provisional 63/516,145
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Chang Gung University Of Science And Technology
OA Round
1 (Non-Final)
37%
Grant Probability
At Risk
1-2
OA Rounds
1y 11m
Est. Remaining
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
297 granted / 794 resolved
-22.6% vs TC avg
Strong +18% interview lift
Without
With
+18.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
55 currently pending
Career history
850
Total Applications
across all art units

Statute-Specific Performance

§101
14.5%
-25.5% vs TC avg
§103
41.1%
+1.1% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
19.6%
-20.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 794 resolved cases

Office Action

§101 §102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-35 are pending. Claims 1-5 are examined on the merits. Claims 6-35 are withdrawn. Election/Restrictions Claims 6-35 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected group, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 7/28/2026. Applicant's election with traverse of Group I (Claims 1-5), the species ultrasonic extraction, alcohols in the reply filed on 7/28/2026 is acknowledged. The traversal is on the ground(s) that there is no burden to search all the groups. This is not found persuasive because a search of one group is not coextensive with the search of the other groups. Thus, it would be burdensome to search the entire claims. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-5 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Claim(s) 1-5 are directed to a composition comprising natural products. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception. MPEP § 2106 sets forth the Subject Matter Eligibility Test to determine if a claim is directed to patent eligible subject matter. Step 1 asks if a claim is directed to a statutory category of invention. Applicant’s claims are directed to a product; thus, the answer to Step 1 is Yes. Step 2A, Prong One, asks if a claim recites to a product of nature. In this case, applicant’s claims Oncidium plant extracts. Thus, the claims do recite products of nature. MPEP § 2106.04(b) states that “When a claim recites a nature-based product limitation, examiners should use the markedly different characteristics analysis discussed in MPEP § 2106.04(c) to evaluate the nature-based product limitation and determine the answer to Step 2A.” MPEP § 2106.04(c)(I) states that “if the nature-based product limitation is not naturally occurring, for example due to some human intervention, then the markedly different characteristics analysis must be performed to determine whether the claimed product limitation is a product of nature exception…”. To perform the markedly different characteristic analysis, MPEP § 2106.04(c)(II) states “The markedly different characteristics analysis compares the nature-based product limitation to its naturally occurring counterpart in its natural state. Markedly different characteristics can be expressed as the product’s structure, function, and/or other properties…”. In this case, in claim 1-2, the dried and alcoholic extraction form the ingredients mixed together would still be a product of nature because as long as there are nature-based molecules found in the composition, the composition contains a mixture of products that are found in nature (the individual natural molecules) and thus must be evaluated as per the described analysis. Mixing together various natural molecules doesn’t change those molecules per se; they are simply mixed together and thus would have the same characteristics as the same molecules prior to being mixed together. Therefore, the answer to Step 2A, Prong One, is Yes. Thus, the analysis must move to Step 2A, Prong Two, which asks if the claim recites additional elements that integrate the judicial exception into a practical application. As discussed in MPEP § 2106.04(d)(2) this evaluation is performed by identifying whether there are additional elements recited in the claim beyond the judicial exception and evaluating these additional elements to determine whether the claim as a whole integrates the exception into a practical application. The homogenized composition of the plant are non-natural. However, a composition can be used in many different ways and thus not integrate the judicial exception into a practical application. Thus, the answer to Step 2A, Prong Two, is No. The analysis must then move to Step 2B which asks if claims recite additional elements that amount to significantly more than the judicial exception. MPEP § 2106.05 states that this evaluation is performed by “Evaluating additional elements to determine whether they amount to an inventive concept requires considering them both individually and in combination to ensure that they amount to significantly more than the judicial exception itself.” The mixing of homogenized plant are well understood, routine, and conventional method of making a product (see rejection below). Thus, the answer to Step 2B is No. Therefore, the claims are not directed to patent eligible subject matter. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lin et al. (CN 105906739 A). Lin et al. teaches a Oncidium is a dendrobe culture embryonic tissue raw ball stem polysaccharides purified comprising 1) 1) drying crushing: taking dry dendrobium stem, 55 to 65 ℃ vacuum drying 2h, and to the dry dendrobium stem after drying by crushing, after crushing to 70 to 90 meshes sieve, to obtain dendrobe powder, 2) ultrasonic water bath extraction: material liquid ratio according to 1: 30 to 35 the ratio after taking dendrobium candidum powder and pure water mixed, place the stainless steel cylinder by ultrasonic wave water bath heating extraction, extraction temperature 40 ~ 55 ℃, extraction time 85 ~ 100 min, ultrasonic wave frequency 40 to 50 kHz, beyond the sound power constant is 280-320 W, obtaining the extract liquid, 3) centrifugal concentration treatment, to obtain the extraction liquid by using centrifugal removing slag, taking supernatant liquid with rotary evaporimeter for concentrated treatment, again with 4 time volume 95% alcohol sediment 7 to 9h (Claim 1). Raw stem ball would include the roots; thus, Claim 4 limitation is taught. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-5 are rejected under 35 U.S.C. 103 as being unpatentable over Lin et al. (CN 105906739 A). Lin et al. teaches a Oncidium is a dendrobe culture embryonic tissue raw ball stem polysaccharides purified comprising 1) 1) drying crushing: taking dry dendrobium stem, 55 to 65 ℃ vacuum drying 2h, and to the dry dendrobium stem after drying by crushing, after crushing to 70 to 90 meshes sieve, to obtain dendrobe powder, 2) ultrasonic water bath extraction: material liquid ratio according to 1: 30 to 35 the ratio after taking dendrobium candidum powder and pure water mixed, place the stainless steel cylinder by ultrasonic wave water bath heating extraction, extraction temperature 40 ~ 55 ℃, extraction time 85 ~ 100 min, ultrasonic wave frequency 40 to 50 kHz, beyond the sound power constant is 280-320 W, obtaining the extract liquid, 3) centrifugal concentration treatment, to obtain the extraction liquid by using centrifugal removing slag, taking supernatant liquid with rotary evaporimeter for concentrated treatment, again with 4 time volume 95% alcohol sediment 7 to 9h (Claim 1). Raw stem ball would include the roots; thus, Claim 4 limitation is taught. However, Lin et al. does not teach the species of Oncidium in Claim 5. Although Lin et al. does not explicitly teach the composition in the form of the species of Oncidium in Claim 5, since the species are all Oncidium, it would clearly have been a natural and obvious choice for a form of the reference composition.Accordingly, It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use the composition as beneficially taught by Lin et al. as a medicine. The adjustment of particular conventional working conditions (e.g., determining suitable formulations and/or which anticancer compositions to combine with the composition and/or appropriate labeling of the food product) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Conclusion No claim is allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 26, 2024
Application Filed
Aug 20, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766179
Oral Formulations Containing Enriched Polyphenolic Compounds together with a Form of Creatine, a Source of Choline and Trisodium Citrate
5y 5m to grant Granted Oct 20, 2026
Patent 12741000
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING PSORIASIS, PREPARATION METHOD THEREFOR AND USE THEREOF
4y 4m to grant Granted Sep 22, 2026
Patent 12697564
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
2y 10m to grant Granted Aug 04, 2026
Patent 12673114
COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING IL-2 SURFACE EXPRESSION-EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT
4y 6m to grant Granted Jul 07, 2026
Patent 12622869
LIPID EMULSION FOR PARENTERAL ADMINISTRATION
5y 4m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.0%)
4y 3m (~1y 11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 794 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month